# MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery)

> **NCT00157716** · PHASE2 · COMPLETED · sponsor: **Medicure** · enrollment: 900 (—)

## Conditions studied

- Coronary Artery Bypass Graft Surgery
- Myocardial Ischemia
- Reperfusion Injury
- Myocardial Revascularization

## Interventions

- **DRUG:** (MC-1) Pyridoxal-5'-phosphate

## Key facts

- **NCT ID:** NCT00157716
- **Lead sponsor:** Medicure
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** —
- **Final completion:** 2005-10
- **Target enrollment:** 900 (—)
- **Last updated:** 2006-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00157716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00157716, "MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00157716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*